A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Terminated · Phase 1, Phase 2 · NCT03311334
Conditions: Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer
At a glance
- Research payments reported, 2025
- $7,913
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 47
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Tested
- DSP-7888 Dosing Emulsion (drug), Nivolumab (drug), Pembrolizumab (drug)
- Dates
- Started 2017-12-14; completion 2022-11-29
- Results posted
- Yes
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search part of the study (Phase 1b and Phase 1b Enrichment Cohort) and the dose expansion part of the study (Phase 2). In Phase 1b of this study there will be 2 arms: Arm 1 and Arm 2. In Arm 1, there will be 6 to 12 patients who will be dosed with DSP-7888 Dosing Emulsion and nivolumab and in Arm 2 there will be 6 to 12 patients who will be dosed with DSP-7888 Dosing Emulsion and pembrolizumab. In addition, an enrichment cohort of a further 10 patients who have locally adva…
From ClinicalTrials.gov, last updated 2024-04-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $7,913 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rutgers the State University $7,913
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.